The lymphomas are a heterogeneous group of cancers of the lymphoidsystem that are of increasing importance to the medical community.There has been a threefold increase in the incidence of thesetumors for reasons that are incompletely understood, and theeffect of therapy on the natural history of lymphomas has beendramatic. Without treatment, these disorders are almost invariablyfatal — survival is measured in months to years, dependingon the subtype. But most patients will benefit from irradiation,chemotherapy, biologic therapy, or combinations of these approaches,even if only transiently, and a proportion of them will be cured.
From the Department of Medical Oncology, St. Bartholomew's Hospital, London.
Related Letters:
Intensive Therapy for Aggressive Lymphoma
Aguiar Bujanda D., Bohn Sarmiento U., Aguiar Morales J., Bolaños-Meade J., Herishanu Y., Zomas A., Skandalis A., Milpied N.
Extract |
Full Text |
PDF
N Engl J Med 2004;
351:98-100, Jul 1, 2004.
Correspondence
This article has been cited by other articles:
Habermann, T. M., Weller, E. A., Morrison, V. A., Gascoyne, R. D., Cassileth, P. A., Cohn, J. B., Dakhil, S. R., Woda, B., Fisher, R. I., Peterson, B. A., Horning, S. J.
(2006). Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma. JCO
24: 3121-3127
[Abstract][Full Text]
Gregory, S. A., Trumper, L.
(2005). Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes?. Ann Oncol
16: 1413-1424
[Abstract][Full Text]
Aguiar Bujanda, D., Bohn Sarmiento, U., Aguiar Morales, J., Bolanos-Meade, J., Herishanu, Y., Zomas, A., Skandalis, A., Milpied, N.
(2004). Intensive Therapy for Aggressive Lymphoma. NEJM
351: 98-100
[Full Text]
(2004). High-Dose Chemotherapy with Stem-Cell Transplantation for Lymphoma. JWatch General
2004: 5-5
[Full Text]
Previous
